To thoroughly implement the future work deployment of Shenzhen Cell Valley and its subsidiaries, clarify work objectives, build consensus on development, and support the shared growth of the company and its employees, the Group convened an all-staff meeting on the afternoon of October 30, 2023. Founder and Chairman Shi Yuanyuan delivered a keynote report titled "Reaching a Growth Inflection Point, Seizing the Opportunities of the Era." Group Deputy General Manager and Chief Scientist Wang Jianxun, Deputy General Managers Xiang Hua and Tang Xiaomeng, and all employees from the Shenzhen headquarters and wholly-owned subsidiaries Junhou Bio and Jing-Shen Cell Valley attended the meeting both online and offline.

Chairman Shi Yuanyuan addressed the meeting on topics including industry situation analysis, honor and performance highlights, internal development, and challenges, opportunities, and goals.

Chairman Shi Yuanyuan first analyzed the development of the domestic and international CGT industry, emphasizing that while the industry as a whole is developing rapidly, exploratory enterprises experience ups and downs, and investment and financing have entered a capital winter. The CGT industry faces a situation where challenges and opportunities coexist. Enterprises increasingly compete on technological strength, management capability, and strategic resolve. As a technology-driven enterprise, we should courageously face challenges, seize the opportunities of the era, strengthen differentiated development, seek suitable profit models, and achieve counter-cyclical growth amid the capital winter.

Chairman Shi Yuanyuan stated that in the year since Shenzhen Cell Valley moved from construction to official operation and production, in accordance with the Board's overall strategic planning and layout, all work including production, R&D, quality control, and marketing has been carried out in an orderly manner. The company has received more than ten honors and municipal and district-level projects, achieved steady market expansion and rapid sales growth, and established comprehensive strategic partnerships with industry leaders such as Lu Daopei International Medical Group and Fosun Kite, with corporate strength growing by the day. Currently, Shenzhen Cell Valley has reached a growth inflection point. We will closely focus on the company's strategic goals, continuously improve product and service quality, enhance core competitiveness, and form corporate advantages. We will also carry out talent cultivation services, cooperate with multiple parties to build an industry ecosystem, and steadily expand into national and overseas markets. At the same time, we will improve corporate management systems, strengthen corporate culture development, and lay a solid foundation for the company's sustained and healthy development.

This keynote report further clarified the company's vision and positioning. All employees of Shenzhen Cell Valley will continue to uphold the original aspiration of "Cells benefit all, genes create the future" and forge ahead with determination. All departments will unify their thinking, strengthen confidence in development, clarify work approaches, define breakthrough goals, effectively enhance the sense of responsibility and urgency in driving the company's development, and go all out to achieve the key tasks and business objectives for 2023.